

UPMC Hillman Cancer Center, Partner with University of Pittsburgh Cancer Institute, and the University of Pittsburgh School of Medicine Center for Continuing Education in the Health Sciences presents:

2022 San Antonio Breast Cancer Symposium Review

Date: Friday, February 17, 2023

Time: 8:00 am to 2:00 pm

Location: UPMC Shadyside Herberman Conference Center and Microsoft TEAMS

Course Directors

Dhaval Mehta, MD

*Clinical Assistant Professor of Medicine
UPMC Hillman Cancer Center,
Monroeville*

Shannon Huggins-Puhalla, MD

*Assistant Professor of Medicine
University of Pittsburgh School of Medicine
UPMC Hillman Cancer Center, Passavant
Magee-Women's Hospital of UPMC*

Program Goal

To provide healthcare professionals knowledge and skills on topics surrounding experimental biology, etiology, prevention, diagnosis, and therapy of breast cancer and premalignant breast disease as discussed at the 2022 SABCR Symposium.

Target Audience

Physicians, researchers, advanced practice providers, nurses, and other health care professionals who work with individuals diagnosed with breast cancer.

Course Objectives

Upon completion of this program, attendees will be able to:

- Identify the most up to date findings in breast cancer clinical and translational research
- Incorporate research findings to appropriately manage patients with breast cancer
- Demonstrate understanding of the scientific findings in breast cancer research by demonstrating competence in the clinical setting

Course Handouts

Presentations will not be printed, but access will be made electronically as approved by faculty following the conference.

Parking

Parking is available in the Medical Center Garage on Centre Avenue. Parking is at your own expense. Validation at registration will allow for a reduced rate of \$5.

Disclaimer

The information presented at this CME program represents the views and opinions of the individual presenters, and does not constitute the opinion or endorsement of, or promotion by, the UPMC Center for Continuing Education in the Health Sciences, UPMC Affiliates, and University of Pittsburgh School of Medicine. Reasonable efforts have been taken intending for educational subject matter to be presented in a balanced, unbiased fashion and in compliance with regulatory requirements. However, each program attendee must always use his/her own personal and professional judgment when considering further application of this information, particularly as it may relate to patient diagnostic or treatment decisions including, without limitation, FDA-approved uses and any off-label uses.

Accreditation and Credit Designation

In support of improving patient care, the University of Pittsburgh is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician (CME)

The University of Pittsburgh designates this live activity for a maximum of 5.0 *AMA PRA Category 1 Credits*[™]. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nursing (CNE)

The maximum number of hours awarded for this Continuing Nursing Education activity is 5.0 contact hours.

Physician Assistant (AAPA)

The University of Pittsburgh has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 5.0 AAPA Category 1 CME credits. PAs should only claim credit commensurate with the extent of their participation.

Other health care professionals will receive a certificate of attendance confirming the number of contact hours commensurate with the extent of participation in this activity.

We gratefully acknowledge support from the following exhibitors for this activity:

Amgen, AstraZeneca, Bayer, Breast Cancer Index, Cancer Bridges, Caris Life Sciences, Daiichi Sankyo, Inc., Foundation Medicine, Gilead Oncology, Lilly Oncology, Merck, Novartis Oncology, Pfizer Oncology, Rigel Pharmaceuticals, Sobi North America, and Tempus Labs, Inc.

Faculty

Parul Barry, MD
Clinical Assistant Professor of
Radiation Oncology
UPMC Magee-Womens Hospital

Julia Foldi, MD, PhD
Division of Medical Oncology
UPMC Hillman Cancer Center

Charles Geyer, MD, FACP
Chief Scientific Officer,
NSABP Foundation
Division of Medical Oncology,
UPMC Hillman Cancer Center

Adam Brufsky, MD, PhD, FACP
Professor of Medicine,
University of Pittsburgh School
of Medicine
Associate Division Chief,
Division of Hematology
Oncology
University of Pittsburgh
Medicine
Medical Director,
Magee Womens Cancer
Program
UPMC Hillman Cancer Center
Co-Director, Comprehensive
Breast Cancer Center
UPMC Magee-Womens Hospital

Emilia Diego, MD
Vice-Chair for Diversity and
Inclusion & Section Chief,
Breast Surgery
Assistant Professor of Surgery
Program Director, Breast
Surgical Oncology Fellowship,
UPMC Magee-Womens Hospital
Director, Pre-Menopausal
Breast Cancer Program, UPMC
Magee-Womens Hospital

Vikram Gorantla, MD
Division of Medical Oncology
UPMC Hillman Cancer Center

Kit Lu, MD
Division of Medical Oncology
UPMC Hillman Cancer Center,
Central Region

Phoung Mai, MD, MS
Associate Professor,
Department of Obstetrics,
Gynecology & Reproductive
Sciences,
UPMC Magee Center for
Medical Genetics and Genomics
UPMC Hillman Cancer Center

Mohammad Rahman, MD
Clinical Assistant Professor,
University of Pittsburgh School
of Medicine
Division of Medical Oncology
UPMC Hillman Cancer Center,
Steubenville

Priya Rastogi, MD
Senior Associate Medical
Director
NSABP Medical Affairs
Associate Professor of Medicine
University of Pittsburgh School
of Medicine
UPMC Hillman Cancer Center

Richard Steinman, MD, PhD
Associate Dean, Director
Medical Scientist Training
Program
University of Pittsburgh

Norman Wolmark, MD, FACS,
FRCS
Professor of Surgery,
University of Pittsburgh
Director, National Cancer
Institute Cooperative Group
Clinical Trials, UPMC Hillman
Cancer Center

Faculty Disclosures

All individuals in a position to control the content of this education activity have disclosed all financial relationships with any companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

All of the relevant financial relationships for the individuals listed below have been mitigated:

Parul Barry, MD, FACRO

Grant/Research Support (ACRO New Practitioner Grant); Consultant (Elsevier Pathway); CE Speakers' Bureau (Varian and OncLive)

Adam Brufsky MD, PhD, FACP

Consultant (AstraZeneca, Pfizer, Novartis, Lilly, Genentech/Roche, SeaGen, Daiichi Sankyo, Merck, Agendia, Sanofi, and Puma); Grant/Research Support (Agendia and Astrazeneca)

Emilia Diego, MD

CE Speakers' Bureau (Clinical Care Options Panel Speaker for CME)

Charles Geyer, MD, FACP

Grant/Research Support (Genentech/Roche, AstraZeneca, Daiichi Sankyo/Astra Zeneca, Abbvie); Consultant (Exact Sciences); Other (Travel, Accommodations, and Expenses (Abbvie, Genentech/Roche, Daiichi-Sankyo, AstraZeneca)

Kit Lu, MD

Consultant (Daichii Sankyo, AstraZeneca, SeaGen, Merck, Stemline, Gilead); Advisory board- Novartis, Pfizer, Biotheranostic, Macrogenetics

Dhaval Mehta, MD

Consultant (AstraZeneca)

No other members of the planning committee, speakers, presenters, authors, content reviewers and/or anyone else in a position to control the content of this education activity have relevant financial relationships with any companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

Agenda

Q&A After Each Session Moderated by Dr Huggins-Puhalla and Dr. Mehta

7:15 am	Registration and TEAMS login	
8:00 am	Welcome	Dhaval Mehta, MD Shannon Huggins-Puhalla, MD
8:10 am	Basic Science Update: Study 21-048 : Platelet-based biomarkers	Richard Steinman, MD, PhD
8:30 am	ER+ Early Stage: GS1-01 : Race and Outcome in RxPONDER, GS1-02 : Racial Disparity in Tumor Microenvironment and Outcomes in Residual Disease Treated with NAC, and GS4-09 : POSITIVE Trial	Kit Lu, MD
8:45 am	GS1-06 : BCI in SOFT trial and GS5-10 : Mammprint and Extended Endocrine Therapy	Mohammad (Pervaiz) Rahman, MD
9:10 am	ER+ Advanced Stage: SERD/PROTAC GS3-01 : EMERALD, GS3-02 : Camizestrant, and GS3-03 : ARV-471 (High priority NRG trials)	Charles Geyer, MD
9:25 am	Non-SERD : GS3-04 : Capivasertib, GS3-06 : PACE Trial, GS1-10 : RIGHT Choice, and GS3-09 : CTC-Driven Choice of First Line Therapy for ER+HER2- MBC-STIC CTC Trial	Vikram Gorantla, MD
9:50 am	HER2 Low: GS203 : TALENT (Summary of Abstracts in HER2 Low Session and Overview of High Priority Trials)	Adam Brufsky, MD, PhD, FACP
10:15 am	Break	
10:30 am	HER2+: GS2-01 : DB02, GS2-02 : DB03, and GS1-09 : MONARChE update	Priya Rastogi, MD
10:50 am	TNBC and Immunotherapy: GS5-11 : TROPICS 02 Survival Data, GS5-02 : GeparOLA, and GS5-03 : I-SPY cemiplimab	Julia Foldi, MD, PhD
11:15 am	Brinker Lecture	Norman Wolmark, MD, FACS, FRCS
12:00 pm	Lunch	
12:45 pm	Genetics and Prevention: GS4-04 : Risk of Contralateral Breast Cancer with Gene Mutations and GS4-08 : Low Dose Tamoxifen Update	Phoung Mai, MD, MS
1:10 pm	Breast Surgery: GS4-01 : BCS and Multiple IPSI Breast Cancers and GS4-02 : Omission of ALND with Conversion to Node (-)	Emilia Diego, MD
1:30 pm	Radiation: GS4-03 : POLAR Trial, GS4-05 : Phase II Randomized Trial of Conventional vs. Hypofractionated Post-Mastectomy Proton Radiotherapy, GS4-06 : Radiomic Phenotypes of Breast Texture and Association with Breast Cancer Risk and Masking, and GS5-12 : Hypofractionated Radiotherapy in Patients with Breast Cancer: Acute Toxicity Data of a Phase III Randomized Study	Parul Barry, MD
1:55 pm	Conclusion	Dhaval Mehta, MD Shannon Huggins-Puhalla, MD
2:00 pm	Adjournment	